SciSparc's NeuroThera opens German Phase IIb site for Tourette drug SCI-110

SciSparc Ltd. announced on July 15, 2026 that its subsidiary NeuroThera Labs Inc. has initiated its Phase IIb clinical trial site at Hannover Medical School in Hanover, Germany, for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome in adults.¹

The trial previously received regulatory clearance from Germany's Federal Institute for Drugs and Medical Devices and MHH's ethics committee, and is now advancing at Hannover Medical School as one of the key clinical sites of the study.¹ SCI-110 combines dronabinol with the endocannabinoid-like compound palmitoylethanolamide in a single dosage form designed to reduce tics and comorbid symptoms in adults with Tourette Syndrome while limiting side effects.¹

Besides Hannover Medical School, the trial will also run at Yale Child Study Center in New Haven, Connecticut, and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel.¹

The Phase IIb design follows earlier Phase IIa results. That earlier study showed an average tic reduction of 21% across the full participant sample, as measured by the Yale Global Tic Severity Scale Total Tic Score, and the Phase IIb study is structured as a randomized, double-blind, placebo-controlled, cross-over trial evaluating the efficacy, safety, and tolerability of daily oral SCI-110.¹ Patients aged 18 to 65 will be randomized to receive either SCI-110 or placebo, with the primary efficacy endpoint measured as the change in tic severity on the Yale Global Tic Severity Scale at weeks 12 and 26 versus baseline.¹ Safety will be monitored through adverse event tracking.¹

SciSparc, through NeuroThera, is also developing SCI-110 for Alzheimer's disease and agitation, and SCI-210 for Autism Spectrum Disorder and status epilepticus.¹